What Aptatek Biosciences does

Aptatek Biosciences, Inc. is a privately held medical device company founded in 2008 and headquartered in Princeton, New Jersey, with a headcount of 1-10 employees. The company is developing a portable biosensing platform that enables real-time home monitoring of chronic disease biomarkers. Its core technology is based on proprietary DNA aptamer sequences developed in the laboratories of Dr. Milan Stojanovic and Dr. Tilla Worgall at Columbia University Medical Center. These aptamer sequences detect small molecule biomarkers that antibodies cannot detect, with sensitivity and specificity that match laboratory mass spectrometry instruments. The Aptatek HomeCheck System combines this aptamer assay technology with a handheld, battery-powered, Bluetooth-enabled device designed for use at home or at point-of-care settings.

The company's first product, PheCheck, is an in-home phenylketonuria (PKU) monitoring test that allows patients to measure phenylalanine levels in real time and adjust their diet immediately to maintain clinically appropriate ranges. PheCheck has received FDA Breakthrough Device designation and is advancing toward FDA clearance through a six-month clinical study expected to commence in the first half of 2026. Lumos Diagnostics Holdings Ltd is providing end-to-end clinical study management services under a contract valued at approximately US$400,000 and has indicated it will pursue commercial manufacturing of PheCheck tests and digital reader upon successful FDA clearance. Beyond PKU, the underlying aptamer platform has been clinically validated with more than 40 small molecule biomarkers that are otherwise not detectable outside laboratory settings, indicating a broader pipeline opportunity.

Aptatek's intended business model centers on hardware sales of disposable test kits and a digital reader component once FDA clearance is secured. Distribution channels are not yet established, but the device is designed for home use and point-of-care settings, suggesting eventual commercialization through healthcare providers, pharmacies, or direct-to-patient channels. The company has raised a $4 million seed round led by IP Group, Inc. in March 2022, with additional follow-on participation in 2024 and 2025. There is no public revenue disclosure and the company is pre-commercial, with no apps, public APIs, or SDKs currently available.

Name

Aptatek Biosciences

Legal name

Aptatek BioSciences, Inc.

Website

https://aptatek.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

1–10 employees

Short description

Aptatek Biosciences develops a portable DNA aptamer-based biosensing platform for real-time home monitoring of chronic disease biomarkers, with its first product PheCheck for phenylketonuria holding FDA Breakthrough Device designation.

Ownership category

akta.pro rank

Product category

Medical Diagnostic Devices

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing) (HLAAALAH)

akta.pro secondary industries

Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers) (HLAAAMAD), Proteomics & Mass Spectrometry Services (HLAGANAB)

Keywords

• Biosensing diagnostics
• Aptamer assays
• Point-of-care testing
• Chronic disease monitoring
• In-home diagnostics

Headquarters

HQ city

Princeton

HQ country

United States

HQ region

North America

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain, Others

Revenue model

1. PheCheck Test Kits: Sale of disposable test kits for the PheCheck in-home phenylketonuria monitoring device. The Lumos Diagnostics partnership mentions potential for commercial manufacturing of PheCheck tests and digital reader upon FDA clearance.
2. PheCheck Digital Reader Device: Sale of the handheld Aptatek HomeCheck device and digital reader component. The device is battery powered and Bluetooth-enabled.
3. Clinical Study Services (via Lumos): Lumos Diagnostics is providing end-to-end clinical study management services on a time-and-materials basis for the PheCheck FDA clearance study, valued at approximately US$400,000.

Go-to-market motion1 record

Marketing channels1 record

Core offering

Aptatek Biosciences is developing a proprietary DNA aptamer-based biosensing platform delivered through the Aptatek HomeCheck System, a handheld, battery-powered, Bluetooth-enabled diagnostic device for real-time in-home monitoring of chronic diseases. Its first product, PheCheck, targets phenylketonuria (PKU) patients by measuring phenylalanine levels in real time, enabling immediate dietary adjustments. The aptamer assay technology detects small molecule biomarkers that cannot be detected by antibodies, with sensitivity and specificity comparable to laboratory mass spectrometry instruments.

Product overview

Aptatek BioSciences is developing a unified home monitoring platform consisting of the Aptatek HomeCheck System and the PheCheck test. The HomeCheck System serves as the core handheld, smartphone-connected diagnostic hardware platform, while PheCheck is the first product application focused on phenylketonuria (PKU) monitoring. The system leverages proprietary DNA aptamer assay technology to detect small molecule biomarkers that cannot be detected by antibodies, with sensitivity and specificity matching laboratory instruments including mass spectrometry.

Differentiator

Problem solved

Functional benefit

Brands

• HomeCheck System: Aptatek's handheld, battery-powered, Bluetooth-enabled device system for home monitoring of chronic diseases.
• PheCheck™

Products and services

• Aptatek HomeCheck System A handheld, smartphone-based diagnostic platform that combines proprietary DNA aptamer assay technology with Bluetooth-enabled hardware for real-time in-home monitoring of chronic diseases. Battery-powered and designed for home or point-of-care use by patients and physicians.
• PheCheck An in-home phenylketonuria (PKU) monitoring test that measures phenylalanine levels in real time, enabling patients to immediately adjust their diet to keep levels within clinical target ranges. Includes a digital reader component and disposable test kits. Designed for patients with phenylketonuria, a chronic genetic disorder requiring lifelong monitoring.

Quantifiable outcome

• Sensitivity and specificity matches laboratory instruments including mass spectrometry

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Lumos Diagnostics Holdings LtdcoreStrategic or Co-development Partner · 1 January 2026Lumos Diagnostics secured a follow-on contract worth approximately US$400,000 with Aptatek to manage a key clinical study advancing the PheCheck in-home phenylketonuria monitoring device toward FDA clearance. The six-month agreement, expected to commence in H1 2026, will see Lumos provide end-to-end clinical study management services on a time-and-materials basis. Subject to successful FDA clearance, Lumos expects to pursue additional commercial manufacturing opportunities for PheCheck tests and digital reader.
• Columbia University (Dr. Milan Stojanovic and Dr. Tilla Worgall)coreStrategic or Co-development PartnerCore technology was developed in the laboratories of Dr. Milan Stojanovic and Dr. Tilla Worgall at Columbia University Medical Center. The founders are faculty members who developed the DNA aptamer technology that forms the basis of Aptatek's proprietary platform.

Scale indicators4 records

Recent moves4 records

Expansion highlights5 records

Direct peers

• Healthy.io: Healthy.io turns the smartphone camera into a clinical-grade home diagnostic (e.g., Minuteful kidney test, urinalysis) with FDA-cleared tests prescribed by clinicians. Closely comparable as a regulated, smartphone-enabled home diagnostic franchise, though Healthy.io's chemistry is colorimetric rather than aptamer-based.
• LumiraDx: LumiraDx developed a microfluidic, smartphone-connected point-of-care diagnostic platform with single-use test strips across immunoassay and molecular panels. Same form factor (handheld reader + consumable strips) and same regulated, point-of-care-plus-home positioning as Aptatek's HomeCheck.
• Cue Health: Cue Health built a regulated, consumer/professional molecular diagnostic reader paired with single-use cartridges for at-home and point-of-care testing. It is the closest direct comparable in business model (handheld reader + disposable test cartridges sold to consumers) even though Cue targets nucleic-acid rather than small-molecule analytes.
• Everlywell: Everlywell sells consumer-facing at-home diagnostic test kits shipped directly to patients. Comparable go-to-market motion (direct-to-patient home testing for chronic markers), though Everlywell relies on mail-in samples with delayed lab results rather than real-time handheld reading.

Broad incumbents

• Abbott (FreeStyle Libre): Abbott's FreeStyle Libre is the closest at-scale analog for a consumer-facing, real-time, home biomarker monitor with consumable sensors. As a large incumbent, Abbott could compete directly if it extends Libre into small-molecule metabolic monitoring or pursues PKU.
• Siemens Healthineers (Atellica / epoc): Siemens Healthineers sells the Atellica clinical chemistry/immunoassay analyzers and the epoc blood-gas point-of-care system. Comparable as a clinical chemistry incumbent with both lab-based and handheld product lines for small-molecule blood analytes.
• Roche Diagnostics: Roche Diagnostics is the global IVD leader with both central-lab and point-of-care franchises (cobas). Roche is the benchmark competitive threat for any new home metabolic-monitoring IVD and represents a likely strategic acquirer for an aptamer-based platform.
• Dexcom: Dexcom is the leading continuous glucose monitor maker (G6/G7), the dominant precedent for a prescribed, wearable, smartphone-connected home biomarker monitor. Aptatek's HomeCheck platform follows the same patient-at-home, Bluetooth-to-phone paradigm but for small-molecule analytes via aptamers rather than enzymatic glucose sensing.
• Bio-Rad Laboratories: Bio-Rad is a major clinical diagnostics and life science research tools manufacturer with products spanning clinical chemistry, immunoassays, and analytical instruments. Aptatek's aptamer-based bench-to-bedside biomarker approach is conceptually adjacent to Bio-Rad's clinical chemistry portfolio.
• QuidelOrtho: QuidelOrtho manufactures a broad range of rapid IVD tests and clinical chemistry/immunoassay analyzers (e.g., Triage MeterPro, Sofia). Comparable business model as a regulated diagnostic device maker with both lab and point-of-care product lines.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aptatek Biosciences